solithromycin
Small moleculeexperimental
Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia and other infections. — Wikipedia
Clinical trial activity
11 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
4
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01168713)
Timeline
Indications
Mechanism of action
- 50S ribosomal protein L2INHIBITOR
rplB inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C- Mol. weight
- 845.02 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1232510 ↗
- WikipediaSolithromycin ↗
- ChEMBLCHEMBL1240704 ↗
Also known as
- cem 101
- cem-101
- cem-101
- cem-101
- cem-101
- op-1068
- op-1068
- solithromycin
- solithromycin
- solithromycin
- solithromycin
- solithromycin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02605122 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2016 | Cempra Inc, Department of Health and Human Services, Duke University |
| NCT02510599 | Phase 2 | Dec 1, 2015 | Cempra Inc |
| NCT02628769 | Phase 2 | Jul 1, 2015 | Cempra Inc, University of London |
| NCT02348424 | Phase 1 | May 5, 2015 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02268279 | Phase 1 | Jan 1, 2015 | Cempra Inc, Department of Health and Human Services, Duke University |
| NCT02210325 | Phase 3 | Aug 1, 2014 | Cempra Inc, National Institute of Allergy and Infectious Diseases (NIAID), University of Melbourne |
| NCT01966055 | Phase 1 | Dec 1, 2013 | Cempra Inc, Department of Health and Human Services, Duke University |
| NCT01968733 | Phase 3 | Nov 1, 2013 | Cempra Inc |
| NCT01756339 | Phase 3 | Dec 1, 2012 | Cempra Inc |
| NCT01591447 | Phase 2 | May 1, 2012 | Cempra Inc, University of Alabama, Birmingham |
| NCT01168713 | Phase 2 | Aug 1, 2010 | Cempra Inc |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cempra Inc | For profit | 10 | 9 | 3 | 2010 |
| Department of Health and Human Services | Government | 3 | 0 | 2 | 2013 |
| Duke University | Academic/Hospital | 3 | 0 | 2 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 1 | 2 | 2014 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2014 |
7 organizations
Page 1 / 1